



PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/735,577
Filing Date	12/12/2003
First Named Inventor	WAISMAN, David
Art Unit	
Examiner Name	
Attorney Docket Number	ME03-009

Total Number of Pages in This Submission

24+

**ENCLOSURES (Check all that apply)**

- |  |   |   |
|--|---|---|
| <input type="checkbox"/> Fee Transmittal Form                                | <input type="checkbox"/> Drawing(s)                                       | <input type="checkbox"/> After Allowance communication to Technology Center (TC)        |
| <input type="checkbox"/> Fee Attached  | <input type="checkbox"/> Licensing-related Papers                         | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences     |
| <input type="checkbox"/> Amendment/Reply                                     | <input type="checkbox"/> Petition   | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final   | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information  |
| <input type="checkbox"/> Affidavits/declaration(s)                           | <input type="checkbox"/> Power of Attorney, Revocation                    | <input type="checkbox"/> Status Letter  |
| <input type="checkbox"/> Extension of Time Request                           | <input type="checkbox"/> Change of Correspondence Address                 | <input type="checkbox"/> Other Enclosure(s) (please identify below):                    |
| <input type="checkbox"/> Express Abandonment Request                         | <input type="checkbox"/> Terminal Disclaimer                              |   |
| <input checked="" type="checkbox"/> Information Disclosure Statement         | <input type="checkbox"/> Request for Refund                               |   |
| <input type="checkbox"/> Certified Copy of Priority Document(s)              | <input type="checkbox"/> CD, Number of CD(s) _____                        |   |
| <input type="checkbox"/> Response to Missing Parts/Incomplete Application    |   |   |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 |   |   |

**Remarks**

IDS references A-T, each of which have multiple pages, are included in this transmittal.

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	Joseph E. Zahner, 48,224
Signature	
Date	March 16, 2004


**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Joseph E. Zahner
Signature	
Date	March 16, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*(Use as many sheets as necessary)*

Sheet 1

of 3

Application Number	10/735,577
--------------------	------------

Filing Date	12/12/2003
-------------	------------

First Named Inventor	WAISMAN, David
----------------------	----------------

Art Unit

Examiner Name \_\_\_\_\_

Attorney Docket Number	ME03-009
------------------------	----------

[illegible][illegible]

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/735,577
		Filing Date	12/12/2003
		First Named Inventor	WAISMAN, David
		Art Unit	
		Examiner Name	
Sheet 2	of 3	Attorney Docket Number	ME03-009

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	B	CAPLAN JF, NR FILIPENKO, SL FITZPATRICK AND DM WAISMAN. Regulation of Annexin A2 by Reversible Glutathionylation. Journal of Biological Chemistry. 279(9): 7740-7750, 2004. USA	
	C	CHOI KS, FOGG DK, YOON CS, WAISMAN DM. p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells. FASEB J. Feb;17(2):235-46, 2003. USA	
	D	CHOI K-S, ET AL. Regulation of Plasmin-Dependent Fibrin Clot Lysis by Annexin II Heterotetramer. Journal of Biological Chemistry. 276(27):25212-25221, 2001. USA	
	E	CHOI K-S, J GHUMAN, G KASSAM, H-M KANG, SL FITZPATRICK AND DM WAISMAN. Annexin II Tetramer Inhibits Plasmin-Dependent Fibrinolysis. Biochemistry. 37:648-655, 1998. USA	
	F	FILIPENKO NR, TJ MACLEOD, C-S YOON AND DM WAISMAN. Annexin A2 is a Novel RNA Binding Protein. Journal of Biological Chemistry. Published online Dec 11 2003. USA	
	G	FILIPENKO NR AND DM WAISMAN. The C Terminus of Annexin II Mediates Binding to F-Actin. Journal of Biological Chemistry. 276(7): 5310-5315, 2001. USA	
	H	FILIPENKO NR AND DM WAISMAN. Characterization of Ca <sup>2+</sup> -binding Sites of Annexin II Tetramer. Journal of Biological Chemistry. 275(49):38877-38884, 2000. USA	
	I	FITZPATRICK SL, G KASSAM A MANRO, CE BRAAT, P LOUIS AND DM WAISMAN. Fucoidan Dependent Conformational Changes in Annexin II Tetramer. Biochemistry. 39:2140-2148, 2000.USA	
	J	FOGG DK, ET AL. The p11 Subunit of Annexin II Heterotetramer is Regulated by Basic Carboxypeptidase. Biochemistry. 41:4953-4961, 2002.USA	
	K	KANG H-M, ET AL. Characterization of Human Recombinant Annexin II Tetramer Purified from Bacteria: Role of N-Terminal Acetylation. Biochemistry. 37:2041-2050, 1997. USA	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/735,577
		Filing Date	12/12/2003
		First Named Inventor	WAISMAN, David
		Art Unit	
		Examiner Name	
Sheet 3	of 3	Attorney Docket Number	ME03-009

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	L	KASSAM G, KWON, YOON, GRAHAM, YOUNG, GLUCK & WAISMAN. Purification and Characterization of A61. Journal of Biological Chemistry. 276(23):8924-8933, 2001. USA	
	M	KASSAM G, ET AL. The Role of Annexin II Tetramer in the Activation of Plasminogen. Journal of Biological Chemistry. 273(8): 4790-4799, 1998. USA	
	N	KASSAM G, ET AL. The p11 Subunit of the Annexin II Tetramer Plays a Key role in the Stimulation of t-Pa-Dependent Plasminogen Activation. Biochemistry. 37:16958-16966, 1998.US	
	O	KWON M, ET AL. Identification of Annexin II Heterotetramer as a Plasmin Reductase. Journal of Biological Chemistry. 277(13):10903-10911, 2002.USA	
	P	LAY AJ, JIANG, KISKER, FLYNN, UNDERWOOD, CONDRON & HOGG. Phosphoglycerate Kinase Acts in Tumour Angiogenesis as a Disulphide Reductase. Nature. 408:869-873, 2000. USA	
	Q	MACLEOD TJ, KWON, FILIPENKO & WAISMAN. Phospholipid associated Annexin AS-S100A10 Heterotetramer and Its Subunits. J Biol Chem. 278(28): 25577-25584, 2003. USA	
	R	STATHAKIS P, FITZGERALD, MATTHIAS, CHESTERMAN & HOGG. Generation of Angiostatin by Reduction and Proteolysis of Plasmin. J Biol Chem. 272(33):20641-29645,1997. USA	
	S	ZHANG L, FOGG & WAISMAN. RNA Interference mediated Silencing of S100A10 Gene Attenuates Plasmin Generation & Invasiveness of Colo 222. J Biol Chem.279(3):2053-2062, 2004.USA	
	T	Fitzpatrick et al., "Regulation of Plasmin Activity by Annexin II Tetramer," Biochemistry 39: 1021-1028, 2000. USA	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.